• Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

CGRP Inhibitors Reduce Migraine Frequency, Disability


The headache community is more than ready for a preventive migraine drug that works. Click through these slides for highlights of recently published trials.

There are numerous studies that suggest far more migraineurs should be on preventive therapy than are currently receiving it; the reasons cited most frequently by patients for not taking the available medications are lack of efficacy or intolerable side effects.A new class of injectble monoclonal antibodies directed against calcitonin gene related peptide (CGRP) or its receptor may be the ideal agents to bridge this treatment gap.There are 4 CGRP inhibitors in competition for FDA approval for migraine prevention: Erenumab (co-developed by Amgen and Novartis)     ERENFremenezumab (Teva)                                                FRENGalcanezumab (Eli Lilly)                                              GALCEptinezumab (Alder Biopharmaceuticals)                    EPTIN Erenumab binds the CGRP receptor; the others bind the CGRP ligand itself. Erenumab has a tentative FDA approval date of May 17, 2018, and the other three will likely follow throughout the summer and fall.Trial results for erenumab and fremenezumab have been published and are summarized in the slides above.  References 1. Lilly's Galcanezumab Significantly Reduces Number of Migraine Headache Days for Patients with Migraine: New Results Presented at AHS [press release]. June 10, 2017. Accessed January 3, 2018. 2. Teva's Fremanezumab Meets all Primary & Secondary Endpoints Across Both Monthly and Quarterly Dosing Regimens in Phase III Study in Episodic Migraine Prevention [press release]. June 7, 2017. Accessed January 3, 2018. 3. Alder BioPharmaceuticals Announces Positive Eptinezumab Phase 3 Results for Prevention of Frequent Episodic Migraine [press release]. June 27, 2017. Accessed January 3, 2018.4. Goadsby PJ, Reuter U1, Hallström Y, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377:2123-2132. doi: 10.1056/NEJMoa17058485. Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377:2113-2122. doi: 10.1056/NEJMoa1709038.

Related Videos
Primary Care is the Answer to the Migraine Care Gap, Says Headache Specialist
Migraine Management Pearls for Primary Care with Neurologist Jessica Ailani, MD
Migraine-specific therapies belong in primary care setting, Jessica Ailani, MD
© 2024 MJH Life Sciences

All rights reserved.